{
    "nctId": "NCT01351597",
    "briefTitle": "A Clinical Trial of Docetaxel and Oxaliplatin in Patients With Recurrent or Metastatic Breast Cancer",
    "officialTitle": "An Open-label, Multi-center Phase II Trial to Evaluate the Efficacy and Safety of Combination Chemotherapy With DoceTaxel(Detaxel) and Oxaliplatin(Oxalitin)in Recurrent or Metastatic Breast Cancer",
    "overallStatus": "UNKNOWN",
    "conditions": "Recurrent Breast Cancer, Metastatic Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 51,
    "primaryOutcomeMeasure": "overall response rate",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Women aged : 20\\~70 years\n2. WHO (ECOG) performance status 0-2\n3. Patients with measurable lesion assessed by imaging using the RECIST (Response Evaluation Criteria In Solid Tumor) guideline\n4. patients had previously not received chemotherapy of recurrent or metastatic lesion.\n5. Have given written informed consent and are available for prolonged follow-up\n\nExclusion Criteria:\n\n1. Patients with previous chemotherapy for recurrent breast cancer\n2. Breast cancer recurrence within 12 months after taxane treatment\n3. Her-2/neu expression breast cancer\n4. Patients with malignancies (other than breast cancer) within the last 5 years, except for adequately treated in situ carcinoma of the cervix or basal cell, squamous cell carcinoma of the skin.\n5. Brain metastasis\n6. uncontrolled infection, medically uncontrollable heart disease\n7. other serious medical illness or prior malignancies\n8. Pregnant or lactating women were excluded.",
    "sex": "FEMALE",
    "minimumAge": "20 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}